Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovac depot in Olea europaea sensitized Rhinoconjunctivitis
NCT02849210Phase 1Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Sep 2015
- Primary completion
- Jun 2017
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Allergovac depot Olea europaea in allergic rhinoconjunctivitis (ARC), sponsored by ROXALL Medizin GmbH. Primary endpoint: Number and severity of adverse reactions at 17 weeks. Started Sep 2015; status: completed.
02
Drugs
Allergovac depot Olea europaea
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02849210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849210.